Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Announces Changes to Board of Directors and Management Team
-- CEO Laurence Cooper Appointed to Board of Directors  -- Francois Lebel to Depart Company BOSTON , Oct. 16, 2018 (GLOBE NEWSWIRE) --   Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies
View HTML
Toggle Summary Ziopharm and Precigen Redefine Relationships, Announce New License Agreement
Ziopharm to Host Conference Call at 8 a.m. BOSTON and GERMANTOWN, Md., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) and Precigen, Inc. , a wholly-owned subsidiary of Intrexon Corporation (Nasdaq: XON), today announced a new definitive license agreement to replace all
View HTML
Toggle Summary Ziopharm Oncology to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
BOSTON , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference in New York on Tuesday, Oct. 2 , at 2:15 p.m. ET .
View HTML
Toggle Summary Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisling Capital, Nominated to Board of Directors
BOSTON , Sept. 04, 2018 (GLOBE NEWSWIRE) -- In a release issued earlier today by  Ziopharm Oncology , Inc. (Nasdaq:ZIOP), please note the Company's upcoming annual meeting of stockholders is being held Sept. 18 rather than Sept. 8 as originally issued.
View HTML
Toggle Summary Ziopharm Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Company Focused on Responding to FDA for Third-generation Trial NCI to file IND for Sleeping Beauty Manufactured TCR-T Cell Therapies Targeting Neoantigens in 4Q2018 Controlled IL-12 Monotherapy, Combination Studies Advancing Changes to Board of Directors and New Staff Illustrate Company Growth
View HTML
Toggle Summary Ziopharm Oncology Announces Changes to its Board of Directors
Scott Tarriff , CEO of Eagle Pharmaceuticals , Elected Lead Director Sir Murray Brennan , M.D., former U.S. Sen. Wyche Fowler to Step Down Paratek Pharmaceuticals CFO Doug Pag á n and Scholar Rock COO Elan Ezickson Nominated to Board Directors BOSTON , Aug.
View HTML
Toggle Summary Ziopharm Oncology to Announce Second Quarter 2018 Financial Results, Host Conference Call Aug. 8
BOSTON , July 31, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast slide presentation on Wednesday, Aug. 8 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the second quarter
View HTML
Toggle Summary Ziopharm Oncology Board Responds to Recent Stock Price Decline
-  Executing on clinical and business development with plans to add new Board members and expand management team   -  Annual meeting of stockholders is Sept. 18 BOSTON , July 26, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next
View HTML
Toggle Summary Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®
Phase 1 trial to evaluate Ad-RTS-hIL-12 plus veledimex in combination with nivolumab for treatment of recurrent glioblastoma BOSTON , June 28, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing
View HTML
Toggle Summary Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy
BOSTON , June 18, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced the U.S. Food and Drug Administration ( FDA ) placed on clinical hold a Phase 1 trial to evaluate CD19-specific CAR-T therapies manufactured under point-of-care and requested additional information in
View HTML